SOURCE: Illumina

DESCRIPTION:

Today, the Montreal Neurological Institute-Hospital at McGill University (The Neuro) announced a new research collaboration with Illumina, along with Takeda Development Center Americas, Inc., and pharmaceutical powerhouse Roche. Driven by the power of Illumina’s WGS capability, the partnership will create a powerful drug discovery platform for neurological conditions such as Parkinson’s disease and REM sleep behavior disorders.

Illumina will support the sequencing of approximately 1,000 patient samples. As the partnership expands with other collaborators, the goal is to complete whole-genome sequencing for 16,000 patients, deep phenotyping of 6,000 patients, and the development of 500 stem cell lines from patients with a wide range of neurological diseases.

"Given the devastating impact of neurological disease on patients and their families, I am inspired by and proud of our work to support the development of individualized treatments for patients in Canada and around the world."

To learn more about the Neuro partnership, read this press release here.

Tweet me: .@TheNeuro_MNI announced a new research collaboration with @illumina, @TakedaPharma, and @Roche. Driven by the power of Illumina’s WGS capability, the partnership will create a powerful drug discovery platform for neurological conditions. Learn more here: https://bit.ly/3B3Bkha

KEYWORDS: illumina, NASDAQ: ILMN, Montreal Neurological Institute-Hospital at McGill University, The Neuro